Liquid Biopsy

Liquid biopsy offers an optimal approach in cases where tissue is unavailable or insufficient for analysis, or when patients need less-invasive sample collection

During the cancer cell lifecycle, DNA is shed and released into the bloodstream. Liquid biopsy testing isolates this circulating tumor DNA – or ctDNA – in order to detect genetic variations which may have prognostic significance and/or inform the therapeutic approach, all from a& simple draw of blood. NeoGenomics offers a broad collection of comprehensive, targeted and single-gene liquid biopsy assays for solid tumor cancer and hematologic malignancies.

InVisionFirst®-Lung Liquid Biopsy

A ctDNA NGA liquid biopsy assay, testing 37 genes relevant to the care of advanced NSCLS patients. Results delivered in 5 days*.

InVisionFirst-Lung Liquid Biopsy


*Turnaround time is 5 days when samples are sent directly to Research Triangle Park (RTP) for processing.

NeoLAB® Solid Tumor Liquid Biopsy

Rapid, high-quality GNS-based genomic profile for pan-cancer, testing 44 genes involved in solid tumor development and progression.

NeoLAB Liquid Biopsy for Solid Tumor

Now offering mobile phlebotomy services

We share your desire to provide all patients with access to timely testing, efficient diagnosis, and seamless progression monitoring. That’s why NeoGenomics is proud to offer in-home specimen collection for liquid biopsy assays through our national mobile phlebotomy program, providing safe and convenient blood draws for liquid biopsy with no added costs for patients.

Learn more about getting timely, accurate, convenient blood-based testing through our National Mobile Phlebotomy Service

For more information contact NeoGenomics Client Services at1-866-776-5907. Download the mobile phlebotomy brochure here.

About Liquid Biopsy


Liquid Biopsy refers to the analysis of blood by whole cancer cells (CTCs) or components of cells such as circulating tumor DNA (ctDNA) in order to characterize solid tumors. During the cancer lifecycle, DNA from our cancer cells break down and shed into the bloodstream, called circulating tumor DNA (ctDNA). From a simple blood draw, liquid biopsy testing can be performed to detect specific genetic variations in the ctDNA of a patient’s blood sample that may be causing the cancer to grow.

Liquid biopsy testing is a novel approach to genomic profiling and has shown to offer several advantages over tissue biopsy for select clinical scenarios. In the case of limited or insufficient tumor tissue or when a repeat biopsy is required for treatment monitoring, liquid biopsy may be a good option for patients largely because it is a minimally invasive procedure. Additionally, the location of the tumor may be difficult or even dangerous to contact for biopsy and testing of ctDNA by a blood draw might be a suitable alternative to traditional tissue biopsy. Lastly, liquid biopsy testing accounts for potential tumor evolution and heterogeneity since the ctDNA comes from cells anywhere in the body, whereas tissue biopsy is a sample taken from an isolated tumor.


Liquid biopsy testing has distinct attributes that can help overcome the limitations of tissue testing and help inform precision oncology decisions. Due to its faster turnaround time, less invasive procedure and it’s ease of use for serial testing, liquid biopsy testing may be an effective approach in the following settings:

  • Inform treatment strategies
  • Monitor disease progression
  • Evaluate therapeutic effectiveness
  • Tissue biopsy is the ‘gold standard’ biospecimen that can provide high diagnostic certainty, but there are characteristic limitations related to difficult biopsy locations, inadequate or insufficient tissue for molecular testing and tumor heterogeneity.
  • Liquid biopsy testing is a minimally invasive approach to detect tumor-derived alterations and tumor heterogeneity. It’s also representative of multiple tumor foci and is an effective and efficient method to simultaneously detect genomic aberrations. Disadvantages to liquid biopsy include its inability to detect the location of tumor mutations, and the lack of diagnostic value if no mutations are detected.
  • Tissue and liquid biopsy testing are complementary approaches and should be individualized for patient care.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients